Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

VSTM shares have climbed 121% over the past three months, fueled by surging revenue from ovarian cancer therapy Avmapki Fakzynja Co-Pack and phase II progress in its KRAS-targeted pipeline. The company posted $25.1 million in Q2 2026 revenue from the ovarian cancer drug, a 1,095% year-over-year increase that signals rapid commercial traction.

The rally also reflects investor anticipation around VS-7375, a KRAS G12D inhibitor currently in phase II trials for pancreatic, lung, and colorectal cancers. VSTM expects to release clinical data for VS-7375 in October 2026 and plans to meet with the FDA before year-end to outline phase III pivotal trial designs. Success in these discussions could set the stage for a registration-enabling study in high-unmet-need oncology indications.

The combination of accelerating commercial revenue and a near-term catalyst in a genetically defined cancer target has driven the three-month breakout. KRAS G12D represents roughly 15% of pancreatic cancers and a subset of non-small cell lung cancer and colorectal cases, providing a sizable addressable market if VS-7375 demonstrates differentiated efficacy or tolerability.